- Funding will support clinical development, manufacturing expansion and commercialization efforts
- Growth hormone, botulinum toxin and recombinant collagen programs anchor the company’s pipeline
Junhemeng Biopharma (君合盟生物制药), a Hangzhou-based biotech startup, has raised nearly 200 million yuan ($29.47 million) in a Series C financing round as the Chinese biotech company advances a pipeline of recombinant protein drugs and medical devices targeting endocrine, neurological and tissue-repair applications.
The round was jointly led by Qiantang Heda Industrial Fund and Hemeng Venture Capital, with Chengshu Investment participating.
Existing investors including Bencao Capital, Guangdian Capital and Hongsheng Capital also increased their stakes.
Founded in Hangzhou, Junhemeng focuses on developing protein therapeutics and medical devices using recombinant technologies. The company said the new capital will be used to advance clinical-stage programs, expand manufacturing capabilities and support future commercialization.
Growth hormone injection
Its lead recombinant human growth hormone injection has completed Phase III clinical trials, while its recombinant botulinum toxin candidate recently dosed the first patient in a Phase III trial for moderate-to-severe glabellar lines.
The company is also developing a portfolio of recombinant collagen products.
Unlike conventional drug discovery approaches that rely heavily on candidate screening, Junhemeng’s platform emphasizes designing protein structures and expression pathways at an early stage through protein engineering and structural biology.
The company says the approach helps reduce manufacturing risks that often emerge during large-scale production.
“Our strategy has always been guided by unmet clinical needs,” said Leng Chunsheng, the company’s founding shareholder and chief scientist. “Leveraging our proprietary technology platforms, we have built a competitive pipeline of recombinant protein therapeutics and medical devices and achieved important clinical milestones across several core programs.”
Junhemeng has established GMP manufacturing facilities in Hangzhou and Tonghua in northeastern China’s Jilin Province, creating an integrated platform spanning early-stage research through commercial production.
The Series C financing follows a string of fundraising rounds over the past four years.
Fundraising journey
The company raised nearly 200 million yuan in a Series A1 round in 2022, close to 100 million yuan in a follow-on Series A+ round in 2023, 100 million yuan in a Series B1 round in 2024 and several tens of millions of yuan in a strategic financing round in 2025.
Investors cited both clinical progress and manufacturing capabilities as key attractions.
“Junhemeng’s development closely aligns with the region’s industrial planning priorities. The company’s R&D pipeline has advanced steadily over the past five years, with strong clinical data performance,” a representative of Qiantang Heda Industrial Fund said. “The investment will help further enhance the industrial ecosystem of Qiantang China Medical Port.”
Qiantang district is a core hub for China’s biopharmaceutical industry in Hangzhou and Zhejiang province, anchored by the dedicated “Hangzhou Medical Port” platform launched in 2017.
The cluster has attracted more than 1,800 biopharma companies and built a full industrial ecosystem spanning research, manufacturing and commercialization.
